AR045950A1 - COMPOUNDS DERIVED FROM PIPERAZINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES. - Google Patents
COMPOUNDS DERIVED FROM PIPERAZINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES.Info
- Publication number
- AR045950A1 AR045950A1 ARP040103493A ARP040103493A AR045950A1 AR 045950 A1 AR045950 A1 AR 045950A1 AR P040103493 A ARP040103493 A AR P040103493A AR P040103493 A ARP040103493 A AR P040103493A AR 045950 A1 AR045950 A1 AR 045950A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alk
- atom
- absent
- groups
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 2
- 239000005977 Ethylene Substances 0.000 abstract 2
- -1 acenaphthyl Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 239000002461 renin inhibitor Substances 0.000 abstract 1
- 229940086526 renin-inhibitors Drugs 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a compuestos derivados de piperazina, composiciones farmacéuticas que los contienen y su uso en la fabricación de medicamentos. Los compuestos son apropiados en especial como inhibidores de la renina y también para ser usados en composiciones farmacéuticas y medicamentos para el tratamiento o prevención de la hipertensión, insuficiencia cardíaca, glaucoma, infarto de miocardio, insuficiencia renal y restenosis. Reivindicación 1: Compuestos de fórmula (1) o (2) en donde: R1 es arilo o heterociclilo; R2 es fenilo, naftilo, acenaftilo, ciclohexilo, piridilo, pirimidinilo, pirazinilo, oxopiridinilo, diazinilo, triazolilo, tienilo, oxazolilo, oxadiazolilo, tiazolilo, pirrolilo, furilo, tetrazolilo o imidazolilo, radicales que pueden estar sustituidos con 1-3 grupos halógeno, hidroxi, ciano, trifluorometilo, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6,. alcoxi C1-6-alquilo C1-6, cianoalquilo C1-6, carboxialquilo C1-6, alcanoiloxi 1-6-alquilo C1-6, alcoxicarboniloxi C1-6-alquilo C1-6, alcoxicarbonilo C1-6 o grupos alcoxi C1-6 o un grupo alquilendioxi C1-6 y/o con un radical L1-T1-L2-T2-L3-T3-L4-T4-L5-U; L1, L2, L3, L4 y L5 son, se modo independiente entre sí, un enlace, alquileno C1-8, alquenileno C2-8 o alquinileno C2-8 o están ausentes; T1, T2, T3 y T4 son, de modo independiente entre sí, (a) un enlace o están ausentes, o uno de los grupos (b) -CH(O)-, (c) -CH(OR6)-, (d) -CH(NR5R6)-, (e) -CO-, (f) -CR7R8-, (g) -O- o -NR6-, (h) - S(O)0-2-, (i) -SO2NR6-, (j) -NR6SO2-, (k) -CONR6-, (l)-NR6CO-, (m) -O-CO-, (n) -CO-O-, (o) -O-CO-O-, (p) -O-CO-NR6-, (q) -N(R6)-CO-N(R6)-, (r) -N(R6)-CO-O-, (s) pirrolidinileno, piperidinileno o piperazinileno, y (t) -C(R11)(R12)-, en donde los enlaces que parten de (b)-(t) llevan a un átomo de C saturado o aromático del grupo adyacente, en caso de que el enlace parte de un heteroátomo, y en donde no más de dos grupos (b)-(f), tres grupos (g)-(h) y un grupo (i)-(t) están ausentes; R3 es H, alquilo C1-6, alquenilo C1-6, alcoxi C1-6, hidroxialquilo C1-6, alcoxi C1-6-alquilo C1-6, bencilo, oxo o un grupo R4-Z1-X1-, en donde R4 es (a) H-, (b) alquilo C1-6-, (c) alquenilo C1-6, (d) hidroxialquilo C1-6, (e) polihidroxialquilo C1-6, (f) alquil C1-6-O-alquilo C1-6-, (g) arilo, (h) heterociclilo, (i) arilalquilo, (j) heterociclilalquilo, (k) ariloxialquilo, (l) heterocicliloxialquilo, (m) (R5,R6)N-(CH2)1-3-, (n) (R5,R6)N-, (o) alquil C1-6-S(O)0-2-, (p) aril-S(O)0-2, (q) heterociclil- S(O)0-2-, (r) HO-SO3- o sus sales, (s) H2N-C(NH)-NH-, y (t) NC-, y los enlaces que parten de (n)-(t) llevan a un átomo de C del grupo adyacente y este átomo de C está saturado, en caso de que el enlace parta de un heteroátomo; Z1 es (a) un enlace, está ausente, o es uno de los grupos, (b) alquileno C1-6, (c) alquenileno C1-6-, (d)-O-, -N(R11)-, -S(O)0-2-, (e) -CO-, (f) -O-CO-, (g) -O-CO-O-, (h) -O-CO-N(R11)-, (i) -N(R11)-CO-O-, (j) -CO-N(R11)-, (k) -N(R11)-CO-, (l) -N(R11)-CO-N-(R11)-, y (m) - CH(OR9)- y los compuestos que parten de (d) y (f)-(m) llevan a un átomo de C del grupo adyacente y este átomo de C está saturado, en caso de que el enlace parta de un heteroátomo; X1 es un enlace, está ausente o es -(CH2)1-3-; R5 y R6 son H, alquilo C1-6, alquenilo C1-6, arilalquilo C1-6 o acilo o, junto con el átomo de N al que están unidos, son un anillo heterocíclico de 5 o 6 miembros que puede contener un átomo de N, O o S adicional o un grupo -SO- o -SO2-, en donde el átomo de N adicional puede estar opcionalmente sustituido con radicales alquilo C1-6; R7 y R8 son junto con el átomo de C al que están unidos, un anillo de 3-7 miembros que puede contener uno o dos átomos de -O- o -S- o grupos -SO- o -SO2-; R9 es H, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6-alquilo C1-6, acilo o arilalquilo; R10 es carboxialquilo, alcoxicarbonilalquilo, alquilo o H, R11 es H o alquilo C1-6 R12 es H o alquilo C1-6; U es H, alquilo C1-6, cicloalquilo, ciano, cicloalquilo opcionalmente sustituido, arilo o heterociclilo; Q es etileno o está ausente (fórmula 1) o es etileno o metileno (fórmula 2); X es un enlace o un grupo >CH-R11, >CR9R11, >CHOR9, >CO o >C=NOR10; Z está ausente o es alquileno C1-6, alquenileno C1-6, hidroxialquilideno C1-6, -CH-R11-CO-NR9-, -O-, -S-, -NR9, -O-Alk-, -S-Alk-, -NR9-Alk-, -Alk-O-, -Alk-S- o -Alk-NR9-, en donde Alk es alquileno C1-6; y en donde (a) en caso de que Z sea -O- o -S-, X es -CR9R11- y R2 contiene un sustituyente L1-T1-L2- T2-L3-T3-L4-T4-L5-U o R3 es un sustituyente distinto de H tal como se definió con anterioridad; (b) en caso de que Z sea -O-Alk-, -S-Alk- o -NR9-Alk-, X es -CR9R11-; y (c) en caso de que X sea un enlace, Z es alquenileno C1-6, -Alk-O-, -Alk-S- o - Alk-NR9-; y sus sales de utilidad farmacéutica.This refers to piperazine-derived compounds, pharmaceutical compositions containing them and their use in the manufacture of medicaments. The compounds are especially suitable as renin inhibitors and also for use in pharmaceutical compositions and medicaments for the treatment or prevention of hypertension, heart failure, glaucoma, myocardial infarction, renal failure and restenosis. Claim 1: Compounds of formula (1) or (2) wherein: R 1 is aryl or heterocyclyl; R2 is phenyl, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, furyl, tetrazolyl or imidazolyl radicals which may be substituted with 1-3 halogen groups hydroxy, cyano, trifluoromethyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl ,. C 1-6 alkoxy-C 1-6 alkyl, C 1-6 cyanoalkyl, C 1-6 carboxyalkyl, C 1-6 alkanoyloxy, C 1-6 alkoxycarbonyloxy-C 1-6 alkyl, C 1-6 alkoxycarbonyl or C 1-6 alkoxy groups or a C1-6 alkylenedioxy group and / or with a radical L1-T1-L2-T2-L3-T3-L4-T4-L5-U; L1, L2, L3, L4 and L5 are, independently of each other, a bond, C1-8 alkylene, C2-8 alkenylene or C2-8 alkynylene or are absent; T1, T2, T3 and T4 are, independently of each other, (a) a link or are absent, or one of the groups (b) -CH (O) -, (c) -CH (OR6) -, ( d) -CH (NR5R6) -, (e) -CO-, (f) -CR7R8-, (g) -O- or -NR6-, (h) - S (O) 0-2-, (i) -SO2NR6-, (j) -NR6SO2-, (k) -CONR6-, (l) -NR6CO-, (m) -O-CO-, (n) -CO-O-, (o) -O-CO -O-, (p) -O-CO-NR6-, (q) -N (R6) -CO-N (R6) -, (r) -N (R6) -CO-O-, (s) pyrrolidinylene , piperidinylene or piperazinylene, and (t) -C (R11) (R12) -, where the bonds that start from (b) - (t) lead to a saturated or aromatic C atom of the adjacent group, in case the link starts from a heteroatom, and where no more than two groups (b) - (f), three groups (g) - (h) and one group (i) - (t) are absent; R3 is H, C1-6 alkyl, C1-6 alkenyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkoxy-C1-6 alkyl, benzyl, oxo or a group R4-Z1-X1-, wherein R4 is (a) H-, (b) C1-6- alkyl, (c) C1-6 alkenyl, (d) C1-6 hydroxyalkyl, (e) C1-6 polyhydroxyalkyl, (f) C1-6-O-alkyl C1-6- alkyl, (g) aryl, (h) heterocyclyl, (i) arylalkyl, (j) heterocyclylalkyl, (k) aryloxyalkyl, (l) heterocyclyloxyalkyl, (m) (R5, R6) N- (CH2) 1 -3-, (n) (R5, R6) N-, (o) C1-6-S-alkyl (O) 0-2-, (p) aryl-S (O) 0-2, (q) heterocyclyl- S (O) 0-2-, (r) HO-SO3- or its salts, (s) H2N-C (NH) -NH-, and (t) NC-, and the bonds starting from (n) - (t) lead to a C atom of the adjacent group and this C atom is saturated, in case the bond starts from a heteroatom; Z1 is (a) a bond, is absent, or is one of the groups, (b) C1-6 alkylene, (c) C1-6 alkenylene, (d) -O-, -N (R11) -, - S (O) 0-2-, (e) -CO-, (f) -O-CO-, (g) -O-CO-O-, (h) -O-CO-N (R11) -, (i) -N (R11) -CO-O-, (j) -CO-N (R11) -, (k) -N (R11) -CO-, (l) -N (R11) -CO-N - (R11) -, and (m) - CH (OR9) - and the compounds that start from (d) and (f) - (m) lead to a C atom of the adjacent group and this C atom is saturated, in case the link starts from a heteroatom; X1 is a link, is absent or is - (CH2) 1-3-; R5 and R6 are H, C1-6 alkyl, C1-6 alkenyl, C1-6 arylalkyl or acyl or, together with the N atom to which they are attached, they are a 5- or 6-membered heterocyclic ring that may contain an atom of Additional N, O or S or a group -SO- or -SO2-, wherein the additional N atom may be optionally substituted with C1-6 alkyl radicals; R7 and R8 are together with the C atom to which they are attached, a 3-7 membered ring that may contain one or two atoms of -O- or -S- or groups -SO- or -SO2-; R9 is H, C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkoxy-C1-6 alkyl, acyl or arylalkyl; R10 is carboxyalkyl, alkoxycarbonylalkyl, alkyl or H, R11 is H or C1-6 alkyl R12 is H or C1-6 alkyl; U is H, C1-6 alkyl, cycloalkyl, cyano, optionally substituted cycloalkyl, aryl or heterocyclyl; Q is ethylene or is absent (formula 1) or is ethylene or methylene (formula 2); X is a link or group> CH-R11,> CR9R11,> CHOR9,> CO or> C = NOR10; Z is absent or is C1-6 alkylene, C1-6 alkenylene, C1-6 hydroxyalkylidene, -CH-R11-CO-NR9-, -O-, -S-, -NR9, -O-Alk-, -S- Alk-, -NR9-Alk-, -Alk-O-, -Alk-S- or -Alk-NR9-, where Alk is C1-6 alkylene; and where (a) in case Z is -O- or -S-, X is -CR9R11- and R2 contains a substituent L1-T1-L2-T2-L3-T3-L4-T4-L5-U or R3 is a substituent other than H as defined above; (b) in case Z is -O-Alk-, -S-Alk- or -NR9-Alk-, X is -CR9R11-; and (c) in case X is a bond, Z is C1-6 alkenylene, -Alk-O-, -Alk-S- or - Alk-NR9-; and its salts of pharmaceutical utility.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH17252003 | 2003-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045950A1 true AR045950A1 (en) | 2005-11-16 |
Family
ID=34438156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103493A AR045950A1 (en) | 2003-10-09 | 2004-09-27 | COMPOUNDS DERIVED FROM PIPERAZINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES. |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR045950A1 (en) |
| TW (1) | TW200528449A (en) |
| WO (1) | WO2005037803A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1707206A1 (en) * | 2005-03-31 | 2006-10-04 | Speedel Experimenta AG | Piperazine derivates for the inhibition of beta-secretase, cathepsin D, plasmepsin ll and HIV protease and for the treatment of malaria, Alzeheimer and AIDS |
| GB0511063D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| WO2007034445A2 (en) * | 2005-09-26 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency |
| WO2007049224A1 (en) * | 2005-10-25 | 2007-05-03 | Actelion Pharmaceuticals Ltd | Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives |
| WO2008074450A2 (en) * | 2006-12-20 | 2008-06-26 | Nicox S.A. | Non-peptidic renin inhibitors nitroderivatives |
| JP5092111B2 (en) * | 2007-02-05 | 2012-12-05 | トーアエイヨー株式会社 | Butoxyaniline derivatives |
| EP2184278A4 (en) * | 2007-08-10 | 2011-08-03 | Nippon Chemiphar Co | P2x4 receptor antagonist |
| TW200932241A (en) | 2007-12-05 | 2009-08-01 | Speedel Experimenta Ag | Organic compounds |
| UY33535A (en) * | 2010-08-13 | 2011-12-01 | Biolab Sanus Farmaceutuca Limitada | DERIVATIVES OF 6,7-DIHIDRO-3H-OXAZOLO [3,4] PIRAZIN-5,8-DIONA |
| US9308163B2 (en) | 2012-02-15 | 2016-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing diseases and disorders of the central nervous system |
| AR099523A1 (en) * | 2014-02-24 | 2016-07-27 | Biolab Sanus Farmacêutica Ltda | COMPOUNDS DERIVED FROM 6,7-DIHIDRO-3H-OXAZOLO [3,4-A] PIRAZINA-5,8-DIONA |
| WO2023178035A1 (en) | 2022-03-14 | 2023-09-21 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL193686B1 (en) * | 1995-09-07 | 2007-03-30 | Hoffmann La Roche | Novel 4-(oxyalkoxyphenyl)-3-oxy piperisiden for treating cardiac and recal insufficiency |
| US6376672B1 (en) * | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
| US6197959B1 (en) * | 1999-04-27 | 2001-03-06 | Hoffmann-La Roche Inc. | Piperidine derivatives |
| GB0119797D0 (en) * | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
| US20040214832A1 (en) * | 2003-04-10 | 2004-10-28 | Cuiman Cai | Piperazine derivative renin inhibitors |
-
2004
- 2004-09-27 AR ARP040103493A patent/AR045950A1/en unknown
- 2004-10-07 TW TW093130312A patent/TW200528449A/en unknown
- 2004-10-07 WO PCT/EP2004/052466 patent/WO2005037803A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW200528449A (en) | 2005-09-01 |
| WO2005037803A1 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106679T1 (en) | AZADICYCLIC HETEROCYCLIC COMPOUNDS AS CANNABINOID RECEPTOR MODIFIERS | |
| NO20021399L (en) | Kazoline derivatives and their use as pharmacists | |
| CY1106674T1 (en) | AZADICYCLIC HETERCYCLES AS CANNABINOID RECEPTOR REGULATORS | |
| CY1105899T1 (en) | PYRIDINOYLOPIPIDINES AS 5-HT1F AGENTS | |
| AR045950A1 (en) | COMPOUNDS DERIVED FROM PIPERAZINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES. | |
| AR053405A1 (en) | SUBSTITUTED UREA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOPATIAS | |
| DK1265606T3 (en) | cell adhesion inhibitors | |
| AR074435A1 (en) | DERIVATIVES OF 1,3-BENZOTIAZOL, DRUGS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF CANCER. | |
| DK1313695T3 (en) | Esters of 5-aminolevulinic acid as photosensitizers in photochemotherapy | |
| NO20085169L (en) | Crystalline solvates and complexes of (1S) -1,5-anhydro-L-C- (3 - ((phenyl) methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes | |
| NO20082389L (en) | 2,3,4-triphenylimidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents | |
| AR025976A1 (en) | FAB INHIBITORS I. | |
| UA25969A1 (en) | DERIVATIVE N- (4-piperidinyl) (OR DYHIDROBENZOFURAN dihydro-2H-BENZOPIRAN) KARBOKSYAMID or their salts, or stereoisomers that stimulate HASTROKYSHKOVU SYSTEM, METHOD OF PRODUCING, intermediates for them, pharmaceutical compositions based on derivatives of N- (4- PIPERIDINIL) (DIHYDROBENZOFURANE OR DIGHYDRO-2H-BENZOPYRANE) CARBOXIAMIDE, WHICH STIMULATES THE GASTROINTESTINAL SYSTEM | |
| NO20062692L (en) | Heterocyclic MEK inhibitors and methods for their use | |
| RU2008142600A (en) | ORGANIC COMPOUND | |
| AR040257A1 (en) | EXCITING AMINO ACID PROFARMS | |
| EA200100600A2 (en) | Diphenylurea compounds, a process for their preparation and pharmaceutical composition containing them | |
| AR055756A1 (en) | SUBSTITUTED PIPERIDINS; PREPARATION PROCESSES AND ITS USE AS MEDICATIONS | |
| NO20053762L (en) | Condensed furan compound. | |
| ATE374773T1 (en) | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | |
| AR057380A1 (en) | CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE AND THERAPEUTIC USE OF THE SAME | |
| ATE159514T1 (en) | SUBSTITUTED AMINO ACID DERIVATIVES USABLE FOR THE TREATMENT OF ARTERIOSCLEROSIS | |
| BG104717A (en) | Water soluble azoles as broad-spectrum antifungals | |
| DK0784620T3 (en) | N-Substituted piperidinyl (bicyclic benzoate) derivatives | |
| NO974690L (en) | Novel triazolones as inhibitors of apolipoprotein B synthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |